Tue, Oct 21, 2014, 9:36 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Chembio Diagnostics, Inc. Message Board

  • mystocks24 mystocks24 Aug 28, 2013 9:26 PM Flag

    No matter how hard you pumpers try

    No matter where u move 200 day average
    U r luck if this holds at 200 line
    Most stocks finish their downtrend way below 200
    0.60 Might be a good support for cemi

    Here's why
    CBRX was trading around 0.60
    When they had $32m Cash
    Around $45m market cap
    And $30m revenue And deal signed with merck untill
    2020
    Let the chart lead you not pumpers here
    And I can't even see where the bottom and base
    I was long this shiet long time, and I was one of the posters here who questioned managements r/s decision
    Management team knew what was coming I wouldn't be surprised to see llawsuits by investors
    Again I am nobody, there are people here with soo much knowledge

    Glta

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Did I even mentioned about lawsuits back then
      Lol forget the direction that was easy one.
      Mo where's 200 day line?
      Didn't I also say " stop pumping cemi"

    • Who's pumping? Management said they have a record second half unfolding....not us.
      Traders worry about price swings...not investors.

    • Of course they knew about Determine Combo. Investors should have known, too, which they clearly didn't. Should CEMI have warned investors? Had they done so, they wouldn't be sitting on nearly $9 million of cash. They did the r/s and nasdaq listing because they wanted access to capital on favorable terms, which they got.

      They aren't doing what they doing to rip off shareholders. They're doing it to try and build the company. Sometimes you have to do what you have to do. That's business.

      • 1 Reply to sonomaca
      • I wanted to point out there is nothing to either pump or bash about this stock. It is simply an established company that is growing numerically, not exponentially (no break out products close to approval). But more than that, they cannot break out until they get control of the reagents that are used for their testing. The antigens (and thereby the antibodies to the antigens) are all other institutions reagents. Those other institutions are all getting the royalty payments that would otherwise be supporting in house R&D for new products. Worked for Baxter Travenol which had 20 years of compounded 20% growth in sales from the 1960s through the 1980s. When I joined them in 1971 they sold $270 million. When I left in 1980 they had $3 billion. Draw the curve in between. Their main products were medical devices made from plastic, solutions, blood fractionation products, Fenwal Transfusion/blood separation products and specialty kits for physicians to order drugs and supplies into their own treatment kits. They sold off Hyland Diagnostics, Medtronics, Flint Pharmaceuticals and Wallerstein Fermentation products. But CEMI has to get a proprietary grip on their own technology or expand their DPP contract capabilities exponentially.

        Sentiment: Buy

 
CEMI
4.04+0.21(+5.48%)Oct 21 3:58 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.